Clinical Acquired Resistance to RAF Inhibitor Combinations in <i>BRAF</i> -Mutant Colorectal Cancer through MAPK Pathway Alterations

Abstract

RAF inhibitor combinations represent promising approaches in clinical development for BRAF-mutant colorectal cancer. Initial characterization of clinical acquired resistance mechanisms to these regimens identified several MAPK pathway alterations driving resistance by reactivating MAPK signaling, highlighting the critical dependence of BRAF-mutant colorectal cancers on MAPK signaling and offering potential strategies to overcome resistance.